Printer Friendly

WHO reports on avian-influenza vaccines--some promising results.

Experts met in February at the World Health Organization (WHO) in Geneva to discuss advances in the development of pandemic-influenza vaccines and reported encouraging progress.

Sixteen manufacturers from 10 countries are developing prototype pandemic-influenza vaccines against the H5N1 avian influenza virus. Five of the manufacturers are also involved in the development of vaccines against other avian viruses (H9N2, H5N2, and H5N3).

At present, more then 40 clinical trials have been completed or are ongoing. Most have focused on healthy adults. Some companies, after completing safety analyses for adults, have initiated clinical trials in the elderly and in children. All the vaccines were safe and well tolerated in all age groups tested.

For the first time, results presented at the meeting have convincingly demonstrated that vaccination with newly developed avian-influenza vaccines can bring about a potentially protective immune response against strains of H5N1 virus found in a variety of geographical locations. Some of the vaccines work with low doses of antigen, which means that significantly more vaccine doses can be available in case of a pandemic.

The WHO meeting, which was convened by the WHO Initiative for Vaccine Research and the WHO Global Influenza Programme, was the third of its kind in just two years. Its objectives were to review progress in the development of candidate vaccines against pandemic influenza viruses and to reach consensus on priority activities for the future.

More than 100 influenza vaccine experts--from academia, national and regional public health institutions, the pharmaceutical industry, and regulatory bodies throughout the world--attended the meeting. Information on more than 20 projects was presented and discussed. Most of the manufacturers are using reference vaccine strains corresponding to H5N1 viruses provided from by WHO Collaborating Centres.

In spite of the encouraging progress noted at the meeting, WHO stresses that the world still lacks the manufacturing capacity to meet potential global demand for a pandemic-influenza vaccine; current capacity is estimated at less than 400 million doses per year of trivalent seasonal-influenza vaccine.

In response to this challenge, WHO launched in 2006 the Global Pandemic Influenza Action Plan (GAP) to increase vaccine supply, an effort that will cost $10 billion over 10 years. One aim of the action plan is to enable developing countries to establish their own influenza vaccine production facilities through transfer of technology, providing them with the most sustainable and reliable response to the threat of pandemic influenza. WHO is currently working with several vaccine producers, mainly in developing countries affected by H5N1, to facilitate establishment of in-country influenza vaccine production.
COPYRIGHT 2007 National Environmental Health Association
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:EH Update
Publication:Journal of Environmental Health
Article Type:Financial report
Date:May 1, 2007
Previous Article:Recreational water illness prevention and swimming pool operation: moving beyond the basics.
Next Article:Space-age tools boost food safety, quality.

Related Articles
On hens and needles.
Harmless virus may aid in knocking out deadly bird flu.
Flu cases jump, but peak of season still weeks away.
Vaccines for pandemic influenza.
Pandemic influenza threat and preparedness (1).
The flu ... and you.
For the birds: new vaccines protect chickens from avian flu.
Bird flu: the facts you need to know.
Avian influenza A (H5NI) age distribution in humans.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters